Retatrutide, a novel dual-acting glucose-responsive incretin agent, represents a significant leap in peptide medicines for the management of type 2 diabetic conditions and, increasingly, excess adiposity. Unlike many existing treatment interventions, retatrutide integrates the actions of a GLP-1 receptor stimulant and a GIP receptor activator, offe